Related Experiment Video

Updated: May 26, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology

Jin Gao1, Yong S Chang, Bahija Jallal

  • 1MedImmune, LLC, Gaithersburg, Maryland, USA.

Cancer Research
|January 5, 2012
PubMed

Insights

Compounds targeting the insulin-like growth factor (IGF) axis show promise for cancer therapy. However, challenges like compensatory insulin receptor activity and glucose homeostasis issues hinder clinical development of these IGF therapies.

Area of Science:

  • Endocrinology and Oncology
  • Molecular Biology and Cancer Therapeutics

Background:

  • Insulin-like growth factors (IGF) are key regulators of cell growth and differentiation with critical roles in cancer development.
  • Dysregulation of the IGF axis is implicated in various cancers, driving research into IGF-targeting therapies.

Purpose of the Study:

  • To review and compare the three main classes of compounds designed to target the IGF axis for cancer treatment.
  • To highlight the challenges in developing IGF-targeted therapies, particularly those arising from cross-reactivity with the insulin signaling pathway.

Main Methods:

  • Review of preclinical and clinical research on IGF-targeting compounds.
  • Comparison of therapeutic antibodies targeting IGF-I receptor (IGF-IR), small molecule tyrosine kinase inhibitors (TKIs) of IGF-IR and insulin receptor (IR), and antibodies targeting IGF ligands.

Main Results:

  • IGF-targeted therapies face hurdles due to homology between IGF and insulin signaling pathways.
  • Inhibition of IGF-IR can lead to compensatory activation of insulin receptor isoform A (IR-A), potentially reducing antitumor efficacy.
  • Inhibition of insulin receptor isoform B (IR-B) can cause glucose homeostasis disturbances.

Conclusions:

  • Understanding the interplay between IGF and insulin signaling is crucial for optimizing IGF-targeted cancer therapies.
  • The three classes of IGF-targeting compounds (anti-IGF-IR antibodies, IGF-IR/IR TKIs, anti-IGF ligand antibodies) present distinct profiles and challenges.
  • Further research is needed to overcome the limitations associated with targeting the IGF axis in cancer treatment.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: